BillionToOne, Inc., began operations as a Delaware corporation in 2016. The company has developed a revolutionary single-molecule next-generation sequencing (smNGS) platform capable of detecting and precisely quantifying gene targets with single-molecule sensitivity. At the heart of this innovation is its patented Quantitative Counting Template (QCT), which measures at the level of a single DNA molecule. This technology breaks through a key bottleneck in healthcare in detecting sparse but clinically significant disease signals in free DNA. BillionToOne's technology platform has been successfully applied to a range of groundbreaking prenatal and oncology products that provide actionable diagnostic information with only a simple blood sample.